The program aims to assist hundreds of people diagnosed with PKU to obtain simple and affordable access to mutation analysis of the PAH gene.
The firms will work to implement MALDI PharmaPulse high-throughput mass spec instrumentation at AMRI's Integrated Drug Discovery Center.
Under the deal, Novartis will access patients who have used Perthera's Precision Cancer Analysis service, which facilitates molecular profiling of cancers.
Infoshield's encryption technology promises the ability to perform calculations and computations without having to first decrypt sensitive data.
The bioinformatics startup has also invested in six other companies, committing $400 million to its data-sharing collaboration.
Imagene will incorporate LifeNome's bioinformatics platform into consumer-facing genetic testing products to be marketed in China and Hong Kong.
As part of the deal, TGen will also become a subsidiary of City of Hope's parent organization, but will remain a non-profit headquartered in Arizona.
Pittsburgh-based Curable is building a coalition to sequence genomes of patients with a rare autoimmune disease of the bile ducts to inform drug development.
The partners are planning a joint research center at Providence Health Care's St. Paul's Hospital in Vancouver and a center of excellence in China.
The agreement lets Biotheranostics offer its CancerType ID and Breast Cancer Index genomic tests to customers through Syapse's software.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.